Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 14 June 2018, 09:11 HKT/SGT
Share:
    

Source: Eisai
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research
Using Novel Nucleic Acid Synthesis and Delivery Technologies Concluded

Research Activities Commence

TOKYO, June 14, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its research subsidiary KAN Research Institute, Inc. has entered into an industry-academia-government joint research agreement with six joint research organizations concerning the "nucleic drug discovery research using novel nucleic acid synthesis and delivery technologies" research project represented by KAN. This joint research project was selected by the Japan Agency for Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) grant program. Believing that creating innovation through industry-academia-government collaboration is an important initiative, Eisai is currently advancing multiple projects, with this project aimed at creating a Japan-originated nucleic acid drug through industry-academia-government collaboration.

Nucleic acid drugs are medicines with a basic structure consisting of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) or chemical modified nucleic acids, and are manufactured via chemical synthesis similar to small molecule drugs. With nucleic acid drugs, it has now become possible to directly act upon intracellular molecules (genes) with high specificity, which are difficult to target with conventional medicines. Based on these characteristics, there are high hopes for drug discovery in many disease areas. On the other hand, there is a need for technologies that can avoid toxicity and a need to establish delivery technologies that can reliably make nucleic acid drugs reach the target cells effectively and safely.

This research project aims to build a proprietary nucleic drug discovery platform by mobilizing innovative nucleic acid technologies for delivery primarily developed by Eisai, artificial nucleic acid synthesis technologies developed by Osaka University, screening technologies established by The National Institute of Biomedical Innovation, Health and Nutrition, nucleic acid production technologies owned by GeneDesign Inc., and then use this platform to discover nucleic acid drug candidates with potentially superior safety and efficacy. Eisai, KAN, Tokyo Women's Medical University, Niigata University and The National Cancer Center Hospital East will cooperate to conduct non-clinical and clinical studies.

As key initiatives for industry-academia-government collaboration in which Eisai is participating, a project aiming to identify and verify novel drug discovery target candidates linked to the development of next-generation treatments and preventative medicines for dementia at the Eisai-Keio Innovation Lab for Dementia (EKID) (Location: Keio University Shinanomachi campus) has also been selected by AMED for the CiCLE program. In addition, an initiative originated in Japan to develop biomedicines and new markers for Crohn's disease represented by Eisai's gastrointestinal disease business subsidiary EA Pharma Co., Ltd. has also been selected by AMED for CiCLE. Furthermore, an initiative for treating inflammatory bowel disease using small molecules and biomarkers through the University of Tsukuba and EA Pharma Co., Ltd. has been adopted by the Japan Science and Technology Agency's Newly extended Technology transfer Program (NexTEP).

By creating new innovation based on industry-academia-government collaboration and fulfilling unmet medical needs, Eisai is striving to contribute to increasing the benefits for patients and their families.

About CiCLE

AMED's CiCLE is a grant program to promote the establishment of infrastructure (including human resources) to respond to medical needs and the creation of an environment for open innovation and venture development based on industry-academia-government collaboration.

About Nucleic Acid Drugs

Nucleic acid drugs are medicines with a basic structure consisting of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) or chemical modified nucleic acids, and are manufactured via chemosynthesis similar to small molecule drugs. With nucleic acid drugs, it has now become possible to directly act upon intracellular molecules (genes) that are highly specific, which are difficult to target with conventional medicines. On the other hand, in order to develop a greater number of various nucleic acid drugs, there is a need for technologies that can avoid toxicity and a need to establish delivery technologies that can reliably make nucleic acids reach the target cells.

There are several types of nucleic acid drugs with differences in structure, targeting and mechanism of action, and pharmaceutical products such as antisense therapies that target RNA as well as aptamers that bind to proteins outside cells and interfere with their function have been approved (including in Japan).

About KAN Research Institute Inc.

KAN Research Institute, Inc. (KAN) is a 100% wholly owned research and development subsidiary of Eisai Co., Ltd. KAN is a research group that aims to discover and develop new drugs based on novel therapeutic concepts in order to fulfill unmet medical needs with truly original science. Initially established with its strengths in Integrative Cell Biology for Medicine, KAN undertakes drug discovery and research activities that seek to find novel disease mechanisms and treatment paradigms by focusing on the characteristics of specific cell types and molecule localization that cause disease. Located within the Kobe Biomedical Innovation Cluster since 2006, KAN established a new research headquarters in 2014 and has continued to develop open innovation with research groups and researchers both within and outside the company. Furthermore, KAN discovered the world's first anti-fractalkine antibody E6011, which is currently being investigated in clinical studies for rheumatoid arthritis, Crohn's disease, and other diseases.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


June 14, 2018 09:11 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
June 21, 2018 09:51 HKT/SGT
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL
June 13, 2018 11:53 HKT/SGT
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA
June 11, 2018 11:44 HKT/SGT
AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA
June 6, 2018 11:16 HKT/SGT
Eisai: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting
June 5, 2018 09:08 HKT/SGT
Eisai: PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months
June 4, 2018 20:10 HKT/SGT
Eisai and Merck Announce Data at 2018 ASCO Annual Meeting
May 31, 2018 12:33 HKT/SGT
U.S. FDA Designates for Priority Review of Eisai's Supplemental New Drug Application for Antiepileptic Drug Fycoma
May 28, 2018 16:06 HKT/SGT
Eisai: PIII Clinical Study Data on Chronic Constipation Treatment "GOOFICE 5mg Tablet" will be Presented at DDW2018
May 25, 2018 14:00 HKT/SGT
Eisai: Potent New Mechanism of Action for Treatment of Inflammatory Bowel Disease
May 25, 2018 10:43 HKT/SGT
Eisai and Merck & Co. Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: